Gilead says it will voluntarily extend 340B pricing to critical access hospitals, sole community hospitals, and rural referral centers on Veklury (remdesivir), its injectable antiviral treatment for COVID-19.

In a Relief to Rural Providers, Gilead Is Waiving 340B Orphan Drug Exclusion for its COVID-19 Drug Veklury

Drug manufacturer Gilead will voluntarily extend 340B pricing to critical access hospitals, sole community hospitals, and rural referral centers on Veklury (remdesivir), its injectable antiviral treatment for COVID-19, the company said late Tuesday.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report